Deutsche Bank Upgrades Novo Nordisk (NVO) to Buy

September 12, 2016 9:18 AM EDT
Get Alerts NVO Hot Sheet
Price: $40.52 -0.71%

Rating Summary:
    8 Buy, 9 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 18 | New: 30
Trade NVO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Deutsche Bank upgraded Novo Nordisk (NYSE: NVO) from Hold to Buy with a price target of DKK 360. Analyst Tim Race anticipates long-term growth.

"We upgrade Novo Nordisk to Buy from Hold, reflecting the company's positive long-term prospects in diabetes," said Race.

The analyst added, "We believe that US price fears in the insulin subsegment are well known and reflected by the company's 24% share price decline YTD (-9% vs SXDP). This leaves the shares trading on 18x 2017E PE, a 15% premium to but a 10 year low versus peers. At these levels we now see upside as the insulin market is not permanently broken and we expect significant growth from GLP-1's."

For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.

Shares of Novo Nordisk closed at $44.04 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Upgrades

Related Entities

Deutsche Bank

Add Your Comment